Alzinova AB (publ) (FRA:78D)

Market Cap	15.21M +13.0%
Revenue (ttm)	13.46K -11.8%
Net Income	-2.20M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0601
Previous Close	0.0614
Day's Range	0.0601 - 0.0601
52-Week Range	0.0067 - 0.2510
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Alzinova AB

Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. The company’s lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer’s disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aβ42, called oligomers, which are considered to be the underlying cause of Alzheimer’s disease; and a humanized version of ALZ-201 in patients with Alz...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 7
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 78D

Financial Performance

In 2025, Alzinova AB's revenue was 252,000, an increase of 740.00% compared to the previous year's 30,000. Losses were -26.27 million, 27.8% more than in 2024.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error